INVEGA SUSTENNA: payments to doctors
Payments that named INVEGA SUSTENNA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $19.9M
- Providers
- 32,547
- Transactions
- 231,829
- Average per transaction
- $86
The per-transaction average — $86 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 32,547 providers the average total is $612, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $19,604,416 | 98.4% |
| Janssen Scientific Affairs, LLC | $312,390 | 1.6% |
| Johnson & Johnson Surgical Vision, Inc. | $224 | 0.0% |
| Abiomed | $181 | 0.0% |
| Actelion Pharmaceuticals US, Inc. | $77 | 0.0% |